Tisagenlecleucel

Global T-Cell Therapy (CAR T-Cell, Tumor Infiltrating Lymphocytes) Market Size, Share & Trends Analysis Report 2019-2026 - ResearchAndMarkets.com

Retrieved on: 
星期五, 十二月 13, 2019
Biotechnology, Pharmaceutical, Health, Medicine, Clinical medicine, Cancer, Cancer treatments, Gene therapy, Immune system, Lymphoma, Tumor-infiltrating lymphocytes, Chimeric antigen receptor T cell, Tumors of the hematopoietic and lymphoid tissues, Tisagenlecleucel, Oncology

The "T-Cell Therapy Market Size, Share & Trends Analysis Report By Modality, By Therapy (CAR T-Cell, Tumor Infiltrating Lymphocytes), By Indication (Hematologic Malignancies, Solid Tumors), And Segment Forecasts, 2019 - 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "T-Cell Therapy Market Size, Share & Trends Analysis Report By Modality, By Therapy (CAR T-Cell, Tumor Infiltrating Lymphocytes), By Indication (Hematologic Malignancies, Solid Tumors), And Segment Forecasts, 2019 - 2026" report has been added to ResearchAndMarkets.com's offering.
  • The global T-cell therapy market size is expected to reach USD 7.51 billion, expanding at a CAGR of 15.4% by 2026
    The landmark approvals of Yescarta and Kymriah have spurred unprecedented advancements in the market.
  • Expansion of the market for T-cell therapy significantly relies on shifting preference from first-line stem cell transplants and chemotherapy to third-line CAR T-cell therapy.
  • Rise in oncological disorders is projected to drive interest as well as investments in the T-cell therapy market in near future.

Global Acute Lymphoblastic Leukemia (ALL) Market Spotlight 2019 Featuring Fate Therapeutics, Novartis, Ono Pharmaceutical - ResearchAndMarkets.com

Retrieved on: 
星期二, 十二月 3, 2019
Pharmaceutical, Health, Oncology, RTT, Cancer treatments, Cancer, Clinical medicine, Leukemia, Acute lymphoblastic leukemia, Forodesine, Tisagenlecleucel

The "Market Spotlight: Acute Lymphoblastic Leukemia (ALL)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Market Spotlight: Acute Lymphoblastic Leukemia (ALL)" report has been added to ResearchAndMarkets.com's offering.
  • This Market Spotlight report covers the Acute Lymphoblastic Leukemia (ALL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
  • The majority of these therapies are administered via the intravenous route, with the remaining products being available in oral and intramuscular formulations.
  • The greatest proportion of industry-sponsored drugs in active clinical development for ALL are in Phase I, with only one drug in Phase III.

CAR-T Therapies Market, 2030 - Current Market Landscape and the Future Potential - ResearchAndMarkets.com

Retrieved on: 
星期一, 九月 30, 2019
Health, Other Health, Medicine, Gene therapy, Clinical medicine, Cancer treatments, Health, Breakthrough therapy, Chimeric antigen receptor T cell, Immune system, Lymphoma, Tisagenlecleucel, Axicabtagene ciloleucel

The CAR-T Therapies Market, 2019-2030 (2nd edition) report features an extensive study of the current market landscape and the future potential of CAR-T cell therapies.

Key Points: 
  • The CAR-T Therapies Market, 2019-2030 (2nd edition) report features an extensive study of the current market landscape and the future potential of CAR-T cell therapies.
  • It is worth highlighting that 66% of the pipeline therapies are presently in the clinical stage.
  • Further research and characterization of these targets have significantly strengthened the pipelines of stakeholder entities engaged in this market.
  • A review of the key promotional strategies that have been adopted by the developers of the marketed CAR-T cell therapies, namely KYMRIAH and YESCARTA.

CHOP Research Team Redefines the Footprint of Viral Vector Gene Therapy

Retrieved on: 
星期二, 七月 30, 2019
Branches of biology, Biology, Life sciences, Genetic engineering, Emerging technologies, Gene therapy, Molecular biology, Biotechnology, Genome editing, Tisagenlecleucel, Cas9, CRISPR

By capturing the full range of gene expression patterns caused by AAV vectors, the technique is expected to significantly advance the already rapidly developing field of gene therapy.

Key Points: 
  • By capturing the full range of gene expression patterns caused by AAV vectors, the technique is expected to significantly advance the already rapidly developing field of gene therapy.
  • Vector technology that was pioneered at CHOP led to the development of the first FDA-approved gene therapies, including Kymriah for B-cell acute lymphoblastic leukemia and Luxturna for inherited retinal disease.
  • CRISPR/Cas9 gene editing machinery, when expressed in cellsevenfor a short time or at low levels, permits targeted DNA editing.
  • In side-by-side comparisons with conventional screening methods, the new method radically redefines the true extent of AAV-mediated gene transfer.

The Case For CAR-T Grows As Responses Hold Up Longer Term - ResearchAndMarkets.com

Retrieved on: 
星期三, 六月 26, 2019
Pharmaceutical, Health, Oncology, Medicine, Life sciences, Clinical medicine, Cancer treatments, Breakthrough therapy, Kite Pharma, Virotherapy, Novartis, Gilead Sciences, Chimeric antigen receptor T cell, Tisagenlecleucel, Axicabtagene ciloleucel

The "The Case For CAR-T Grows As Responses Hold Up Longer Term" newsletter has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The Case For CAR-T Grows As Responses Hold Up Longer Term" newsletter has been added to ResearchAndMarkets.com's offering.
  • Longer-term data is in for CAR-T therapies from Novartis AG and Gilead Sciences, Inc. (via Gilead-owned Kite Pharma, Inc.) and the results show that certain patients who responded to Kymriah and Yescarta have maintained those responses 18 months on.
  • Find out what this means to those in the CAR-T space in this interview with Pascal Touchon, Novartis' Senior Vice President and Global Head, Cell & Gene Therapy, who spoke with Scrip during the last American Society of Hematology meeting in San Diego.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20190626005681/en/

Kymriah (tisagenlecleucel; Novartis) Overview 2019 - ResearchAndMarkets.com

Retrieved on: 
星期三, 六月 26, 2019
Pharmaceutical, Health, Oncology, Non-Hodgkin lymphoma, Medicine, Clinical medicine, Breakthrough therapy, Medical specialties, RTT, Gene therapy, Tisagenlecleucel, Lymphoma, Large-cell lymphoma, B-cell lymphoma, Follicular lymphoma

Kymriah sales for CLL across the US and five major EU markets, by country, 2017-26

Key Points: 
  • Kymriah sales for CLL across the US and five major EU markets, by country, 2017-26
    Kymriah sales for follicular lymphoma across the US, Japan, and five major EU markets, by country, 2017-26
    Kymriah sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2017-26
    Kymriah sales for follicular lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017-26
    Kymriah sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017-26
    View source version on businesswire.com: https://www.businesswire.com/news/home/20190626005412/en/

2018-2019 Pharmaceuticals Research Review - Analysis on Cognition & Memory Enhancement Drugs; Circulating Tumor Cell (CTC) Diagnostics; Viral Vector Manufacturing; Checkpoint Inhibitors; and more - ResearchAndMarkets.com

Retrieved on: 
星期一, 二月 25, 2019
Health, Pharmaceutical, Health sciences, Health, Branches of biology, Gene therapy, Cancer treatments, Breakthrough therapy, Novartis, Tisagenlecleucel, Chimeric antigen receptor T cell, Medication, Pharmaceutical industry, Therapy

The pharmaceutical sector is undergoing expansions driven by the unmet need in several disease areas.

Key Points: 
  • The pharmaceutical sector is undergoing expansions driven by the unmet need in several disease areas.
  • Launch of novel therapies, that included cell and gene therapy with an increase in access to medicines is also driving the growth of the pharmaceutical market.
  • The approval of second CAR T-cell therapy tisagenlecleucel (Kymriah) in 2018 signifies the dramatic progress in the field.
  • Pharma sector ratifies this trend with a rich cancer pipeline, availability of clinical and real-world data and an increase in associated investments.

Global CAR-T Cell Therapy Market Size, Forecasts, Trials & Trends 2019: Increasing Investments, Major Acquisitions and Large IPOs Driving The Future - ResearchAndMarkets.com

Retrieved on: 
星期一, 二月 18, 2019
Health, Biotechnology, Oncology, Pharmaceutical, Medicine, Clinical medicine, Cancer treatments, Cancer, Gene therapy, Breakthrough therapy, Lymphoma, Kite Pharma, Virotherapy, Tisagenlecleucel, Chimeric antigen receptor, Axicabtagene ciloleucel

The "Global CAR-T Cell Therapy Market - Market Size, Forecasts, Trials & Trends" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global CAR-T Cell Therapy Market - Market Size, Forecasts, Trials & Trends" report has been added to ResearchAndMarkets.com's offering.
  • Gilead/Kite Pharma's Yescarta was authorized as a treatment for adult patients with relapsed or refractory DLBCL and primary mediastinal large B-cell lymphoma (PMBCL).
  • Health Canada approved Kymriah as the first CAR-T therapy in Canada and the Therapeutic Goods Administration (TGA) approved it as the first CAR-T therapy in Australia.
  • Novartis produced Kymriah, a CAR-T therapy used to treat leukemia, while Gilead/Kite Pharma developed Yescarta, a CAR-T therapy for patients with lymphomas.

Cell Therapy Market to Grow Beyond Oncology As Big Pharma Expands Investments

Retrieved on: 
星期四, 一月 17, 2019
Biology, Biotechnology, Nature, Gene therapy, Cell biology, Stem cells, Cancer treatments, Novartis, Chimeric antigen receptor, Tisagenlecleucel, Cell therapy, Stem cell

"Novartis and Gilead are among the first companies to adopt this pricing model for their ground-breaking CAR-T Cell therapies Kymriah and Yescarta, respectively.

Key Points: 
  • "Novartis and Gilead are among the first companies to adopt this pricing model for their ground-breaking CAR-T Cell therapies Kymriah and Yescarta, respectively.
  • With more than 959 ongoing regenerative medicine clinical trials, the market finds opportunity across both stem cell and non-stem cell based therapies.
  • Growth Opportunities in the Global Cell Therapy Market, Forecast to 2025is part of Frost & Sullivan's global Life Sciences Growth Partnership Service program.
  • Growth Opportunities in the Global Cell Therapy Market, Forecast to 2025

Cell Therapy Market to Grow Beyond Oncology As Big Pharma Expands Investments

Retrieved on: 
星期四, 一月 17, 2019
Biology, Biotechnology, Nature, Gene therapy, Cell biology, Stem cells, Cancer treatments, Novartis, Chimeric antigen receptor, Tisagenlecleucel, Cell therapy, Stem cell

"Novartis and Gilead are among the first companies to adopt this pricing model for their ground-breaking CAR-T Cell therapies Kymriah and Yescarta, respectively.

Key Points: 
  • "Novartis and Gilead are among the first companies to adopt this pricing model for their ground-breaking CAR-T Cell therapies Kymriah and Yescarta, respectively.
  • With more than 959 ongoing regenerative medicine clinical trials, the market finds opportunity across both stem cell and non-stem cell based therapies.
  • Growth Opportunities in the Global Cell Therapy Market, Forecast to 2025is part of Frost & Sullivan's global Life Sciences Growth Partnership Service program.
  • Growth Opportunities in the Global Cell Therapy Market, Forecast to 2025